Categories

GLP-1s’ direct and indirect impacts on health care and consumer goods – Jane speaks with Bloomberg BNN

Today, I spoke live with Paul Bagnell, news anchor with Bloomberg BNN, on the topic of the GLP-1 agonists and their impact on health care, industries beyond health and medicine, and consumers. In this post, I’ll share with you some of the plotline for our discussion.               Gallup polled U.S. adults in March to gauge their experience with injectable weight loss drugs, the results published earlier this week. The first chart tells us that 6% of people have used these drugs, and 3% were doing so in March. Consumers using the meds were more

 

Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA’s 2024 Update

In the past year, the growth of prescription drug utilization and spending has much to do with the use of GLP-1 agonists to treat diabetes and obesity, along with immunology therapy, and lipid meds, along with specialty medicines now accounting for over half of spending — up from 49% in 2018. This update comes from The Use of Medicines in the U.S. 2024 from the IQVIA Institute for Human Data Science. The annual report details trends in health services utilization, the use of prescription drugs, patient financing of those costs, the drivers underpinning the medicines spending, and an outlook to 2028.

 

Telehealth Legislation Passes Ways & Means, As GLP-1s Are Fast-Meshing with Telemedicine in the Marketplace

Yesterday, the U.S. House Committee on Ways and Means passed six pieces of legislation that would bolster telehealth in the U.S. for the next two years, assuring several aspects of access for health citizens across the country. “One of our top priorities on this Committee is helping every American access health care in the community where they live, work, and raise a family,” Committee Chairman Jason Smith (R-Mo.) explained in his introductory statement. Being from Missouri, Chairman Smith is especially keen on the role virtual care and telehealth can play to expand access to the under-served in the U.S. “In rural

 

Considering Equity and Consumer Impacts of GLP-1 Drugs – A UBS Economist Weighs In

Since the introduction of GLP-1 drugs on the market, their use has split into two categories: for obesity and “recreationally,” according to the Chief Economist with UBS (formerly known as Union Bank of Switzerland). Paul Donovan, said economist, discusses The economics of getting thin in his regularly published comment blog.                   “These different uses have different economic consequences,” Donovan explains: Obese patients who use GLP-1s should become more productive employees, Donovan expects — less subject to prejudice, and less likely to be absent from work. While so-called recreational GLP-1 consumers may experience these